Tirzepatide Spray
Frequently Bought Together
Tirzepatide Spray by BeaCapra — premium research-grade compound verified to ≥99.0% purity via independent HPLC and LC-MS analysis.
Supplied as a pre-dissolved metered nasal spray solution in a 30ml amber glass atomizer with precision dosing mechanism. Each actuation delivers a consistent, measured dose for reliable experimental protocols.
Specifications
- Purity: ≥99.0% (HPLC verified)
- Form: Pre-Dissolved Metered Spray (30ml)
- Category: Metabolic Research
- Storage: -20°C recommended, protect from light
Quality Assurance
Every BeaCapra product ships with a Certificate of Analysis (COA) documenting purity verification via HPLC and mass spectrometry. Our compounds are synthesized under strict GMP-adjacent protocols and undergo batch-level quality control.
For Research Use Only (RUO). Not intended for human consumption, therapeutic, or diagnostic use.
Research-Documented Benefits
- Dual Incretin Agonism — Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic metabolic effects not achievable with single-receptor agonists.
- Superior Weight Reduction — SURMOUNT clinical trials demonstrated mean weight loss of up to 22.5% from baseline at the highest dose, exceeding all prior pharmacological interventions.
- Glycemic Control — Research shows HbA1c reductions of up to 2.4%, with over 95% of study participants achieving target levels below 7%.
- Insulin Sensitivity — Studies demonstrate improved insulin sensitivity in both hepatic and peripheral tissues, with reduced fasting insulin levels.
- Cardiovascular & Metabolic Markers — Significant reductions in triglycerides, blood pressure, and inflammatory markers observed across clinical trial programs.
Mechanism of Action
Tirzepatide is a synthetic 39-amino acid peptide that functions as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist—the first approved molecule to activate both incretin receptor systems.
Primary Pathways
- GIP Receptor Agonism — Activates GIP receptors on pancreatic beta cells (enhancing insulin secretion), adipocytes (improving lipid metabolism), and CNS neurons (modulating appetite and energy expenditure).
- GLP-1 Receptor Agonism — Simultaneously activates GLP-1 receptors, providing complementary effects on insulin secretion, glucagon suppression, and appetite reduction.
- Synergistic Weight Loss — Dual receptor activation produces weight loss exceeding what either GIP or GLP-1 agonism achieves alone, potentially via enhanced adipose tissue lipolysis and central appetite suppression.
- Beta Cell Function — Improves first-phase and second-phase insulin secretion, enhancing overall beta cell glucose responsiveness beyond single-incretin agents.
Tirzepatide's C20 fatty diacid acylation at Lys20 provides albumin binding for a once-weekly duration of action. Its imbalanced agonism (greater GIP potency, attenuated GLP-1 potency) may explain its superior tolerability and efficacy profile.
Research Protocol Guidelines
All protocols described are for in vitro and in vivo research purposes only. Not for human use.
Reconstitution
Reconstitute lyophilized tirzepatide with bacteriostatic water. The C20 fatty diacid modification requires careful reconstitution—add water gently and allow full dissolution without shaking.
Research Dosing (Published Clinical Literature)
- Dose escalation protocol: 2.5 mg SC weekly for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then optional escalation to 10 mg, 12.5 mg, or 15 mg weekly
- Weight management studies: Target doses of 5 mg, 10 mg, or 15 mg weekly in SURMOUNT trial programs
- Glycemic studies: 5-15 mg weekly in SURPASS diabetes research programs
Storage
Store lyophilized form at 2-8°C. Reconstituted at 2-8°C, use within 21 days. Tirzepatide is light-sensitive; store in amber or opaque containers. Do not freeze.
Safety & Handling Information
For research use only. Not intended for human or veterinary diagnostic or therapeutic use.
Storage Requirements
- Lyophilized: 2-8°C (do not freeze)
- Reconstituted: 2-8°C, use within 21 days
- Light-sensitive; store in amber containers
Clinical Safety Data
Tirzepatide has been evaluated in the SURPASS and SURMOUNT trial programs. Its dual-agonist mechanism produces a safety profile related to both GIP and GLP-1 receptor activation.
Known Considerations
- GI adverse events (nausea, diarrhea, constipation) are common, particularly during dose escalation, but generally milder than single GLP-1 agonists at equivalent efficacy doses
- Same GLP-1 class warnings apply: pancreatitis risk, rodent thyroid C-cell findings, gallbladder events
- Hypoglycemia risk when combined with insulin or sulfonylureas in diabetic research models
- Heart rate increases of 2-4 bpm observed in clinical trials
- Allergic reactions at injection site reported in clinical studies (local, not systemic)
Handling
Standard laboratory PPE. Handle similarly to semaglutide. The C20 fatty diacid modification may increase surface adsorption—use low-binding laboratory consumables for dilute preparations.
Frequently Asked Questions
Why does dual GIP/GLP-1 agonism produce better results than GLP-1 alone?
GIP and GLP-1 act on distinct receptors with complementary downstream effects. GIP receptor activation in adipose tissue promotes lipid metabolism and energy expenditure, while GLP-1 receptor activation primarily affects appetite, gastric emptying, and insulin secretion. The combined activation engages metabolic pathways that neither hormone reaches alone.
What is "imbalanced agonism" and why does it matter?
Tirzepatide has ~5x greater potency at the GIP receptor compared to its GLP-1 receptor activity. This "imbalanced" design may explain its improved GI tolerability (less nausea than pure GLP-1 agonists at equivalent metabolic efficacy) while maintaining strong weight loss through GIP-mediated mechanisms.
How does tirzepatide compare to semaglutide in published research?
The SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg. Tirzepatide at all three doses (5, 10, 15 mg) produced superior HbA1c reduction and weight loss compared to semaglutide 1 mg, establishing the dual-agonist approach as more effective than single GLP-1 agonism in head-to-head comparison.
What dose escalation schedule should research protocols follow?
Published clinical protocols use a conservative 4-week step-up: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly. Each step allows GI adaptation. Most research targets 5 mg, 10 mg, or 15 mg as the maintenance dose depending on study endpoints.
Related formulas
Customer Reviews
Exceptional purity and fast shipping
Third-party COA verified at 99.1% purity. Arrived in 2 days with proper cold packaging. The documentation included was thorough and professional. Will be ordering again for our lab.
Best supplier I've found
After trying several suppliers, BeaCapra consistently delivers the highest quality compounds. The subscribe & save option is a great value, and their customer support team answered all my questions promptly.
Great product, COA checks out
Ran our own HPLC analysis and confirmed the purity claims. Packaging was secure and discreet. Only minor note — would love to see more size options for some of the newer compounds. Otherwise excellent.
Subscribe & save is the way to go
The 15% discount on subscription makes this the most competitive pricing I've found for research-grade compounds at this purity level. Auto-delivery every 30 days has been seamless. Highly recommend.
Exactly what our research team needed
We've been sourcing from BeaCapra for our university lab and the consistency batch-to-batch is impressive. Every order comes with a COA and the compounds are properly lyophilized. Professional operation all around.
Questions About Tirzepatide Spray
General Questions
Everything you need to know about BeaCapra research peptides, ordering, shipping, and our commitment to quality.
Still have questions? Our research specialists are here to help.
Contact Us